13.90
+0.55(+4.12%)
Currency In USD
| Previous Close | 13.35 |
| Open | 13.22 |
| Day High | 14.46 |
| Day Low | 12.92 |
| 52-Week High | 41.8 |
| 52-Week Low | 5.01 |
| Volume | 21,824 |
| Average Volume | 625,641 |
| Market Cap | 8.18M |
| PE | -0.48 |
| EPS | -29.17 |
| Moving Average 50 Days | 14.25 |
| Moving Average 200 Days | 9.62 |
| Change | 0.55 |
If you invested $1000 in Quoin Pharmaceuticals, Ltd. (QNRX) since IPO date, it would be worth $0.87 as of December 25, 2025 at a share price of $13.9. Whereas If you bought $1000 worth of Quoin Pharmaceuticals, Ltd. (QNRX) shares 5 years ago, it would be worth $10.03 as of December 25, 2025 at a share price of $13.9.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies
GlobeNewswire Inc.
Nov 11, 2025 1:30 PM GMT
Target Loadings of 4% and 5% Rapamycin Achieved for Topical Lotion and Dermal Patch Delivery Technologies Respectively Clinical Trial and Stability Batch Manufacture to Commence in Q4 2025 Clinical Testing in a Number of Indications Including Microcy
Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025
GlobeNewswire Inc.
Oct 30, 2025 12:30 PM GMT
ASHBURN, Va., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provi
Quoin Pharmaceuticals Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 month ‘Whole Body’ Data Update from Ongoing Study
GlobeNewswire Inc.
Oct 28, 2025 12:30 PM GMT
Recruitment of Three Additional Pediatric Patients in Austria and Ireland Achieves Investigator Study TargetCurrent Pediatric Patient in Ongoing Study Has Completely Healed Skin After 9 months of ‘Whole Body’ TreatmentInvestigator’s Global Assessment